Equities analysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will announce $6.38 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Xenon Pharmaceuticals’ earnings, with estimates ranging from $250,000.00 to $12.50 million. Xenon Pharmaceuticals posted sales of $380,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 1,578.9%. The firm is expected to report its next quarterly earnings report on Wednesday, March 14th.

On average, analysts expect that Xenon Pharmaceuticals will report full year sales of $6.38 million for the current financial year, with estimates ranging from $550,000.00 to $12.80 million. For the next year, analysts expect that the business will report sales of $13.50 million per share. Zacks’ sales calculations are an average based on a survey of analysts that follow Xenon Pharmaceuticals.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Jefferies Group set a $5.00 target price on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th.

Shares of Xenon Pharmaceuticals (NASDAQ XENE) traded up $0.02 on Wednesday, hitting $2.35. 19,900 shares of the stock traded hands, compared to its average volume of 92,797. Xenon Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $9.95.

In other news, Director Mohammad Azab bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $2.22 per share, with a total value of $33,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 9.40% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Scotia Capital Inc. raised its holdings in shares of Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 9,426 shares during the last quarter. KCG Holdings Inc. purchased a new position in shares of Xenon Pharmaceuticals in the first quarter worth $122,000. K2 Principal Fund L.P. raised its holdings in shares of Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 47,535 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares during the last quarter. Finally, DAFNA Capital Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 11.2% in the second quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 38,081 shares during the last quarter. 51.95% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/29/analysts-anticipate-xenon-pharmaceuticals-inc-xene-will-announce-quarterly-sales-of-6-38-million.html.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.